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Abstract: Given the increase in antibiotic-resistant bacteria, alongside the alarmingly low rate of newly
approved antibiotics for clinical usage, we are on the verge of not having effective treatments for
many common infectious diseases. Historically, antibiotic discovery has been crucial in outpacing
resistance and success is closely related to systematic procedures—platforms—that have catalyzed the
antibiotic golden age, namely the Waksman platform, followed by the platforms of semi-synthesis and
fully synthetic antibiotics. Said platforms resulted in the major antibiotic classes: aminoglycosides,
amphenicols, ansamycins, beta-lactams, lipopeptides, diaminopyrimidines, fosfomycins, imidazoles,
macrolides, oxazolidinones, streptogramins, polymyxins, sulphonamides, glycopeptides, quinolones
and tetracyclines. During the genomics era came the target-based platform, mostly considered a failure
due to limitations in translating drugs to the clinic. Therefore, cell-based platforms were re-instituted,
and are still of the utmost importance in the fight against infectious diseases. Although the antibiotic
pipeline is still lackluster, especially of new classes and novel mechanisms of action, in the post-genomic
era, there is an increasingly large set of information available on microbial metabolism. The translation
of such knowledge into novel platforms will hopefully result in the discovery of new and better
therapeutics, which can sway the war on infectious diseases back in our favor.
Keywords: antibiotic discovery platforms; drug screening; semi-synthesis; fully synthetic antibiotics;
genomics; proteomics; metabolomics; lipidomics; metagenomics
1. Introduction—The Desperate Need for New Antibiotics
Infectious diseases have been a challenge throughout the ages. From 1347 to 1350, approximately
one-third of Europe’s population perished to Bubonic plague. Advances in sanitary and hygienic
conditions sufficed to control further plague outbreaks. However, these persisted as a recurrent public
health issue. Likewise, infectious diseases in general remained the leading cause of death up to the
early 1900s, e.g., accounting for 25% of England’s mortality. However, by the mid-1900s, the mortality
of infectious diseases in England shrunk to under 1% after the commercialization of antibiotics [1],
which given their impact on the fate of mankind, were regarded as a ‘medical miracle’. Moreover, the
non-therapeutic application of antibiotics has also greatly affected humanity, for instance those used as
livestock growth promoters to increase food production after World War II.
The term ‘antibiotic’ was introduced by Selman Waksman as any small molecule, produced by
a microbe, with antagonistic properties on the growth of other microbes [2]. An antibiotic interferes
with bacterial survival via a specific Mode-Of-Action (MOA) but more importantly, at therapeutic
concentrations, it is sufficiently potent to be effective against infection and simultaneously presents
minimal toxicity. Most antibiotic classes in use today were identified in the 1940–1960s, a period
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referred to as the antibiotic golden age. During this period, it was common belief that, given the
antibiotics discovered and particularly the rate at which they were discovered, infectious diseases
would soon be a controlled public health issue [3,4]. In fact, in 1970, the US Surgeon General stated
“It’s time to close the book on infectious diseases . . . and shift national resources to such chronic
problems as cancer and heart disease” [5].
Currently, more than 2 million North Americans acquire infections associated with antibiotic resistance
every year, resulting in 23,000 deaths [6]. In Europe, nearly 700 thousand cases of antibiotic-resistant
infections directly develop into over 33,000 deaths yearly [7], with an estimated cost over €1.5 billion [8].
Despite a 36% increase in human use of antibiotics from 2000 to 2010 [9], approximately 20% of deaths
worldwide are related to infectious diseases today [10]. This situation deteriorated further as nosocomial
infections became a leading cause of morbidity and mortality [11], resulting in lengthier hospital stays and
increased health care costs [12]. Furthermore, over 15% of nosocomial infections are already caused by
multidrug-resistant pathogens [13]—for some of which, there are no effective antimicrobials [14]. Future
perspectives are no brighter, for instance, a government commissioned study in the United Kingdom
estimated 10 million deaths per year from antibiotic resistant infections by 2050 [15].
The increase in drug-resistant pathogens is a consequence of multiple factors, including but
not limited to high rates of antimicrobial prescriptions, antibiotic mismanagement in the form of
self-medication or interruption of therapy, and large-scale antibiotic use as growth promotors in
livestock farming [16]. For example, 60% of the antibiotics sold to the USA food industry are also
used as therapeutics in humans [17]. To further complicate matters, it is estimated that $200 million
is required for a molecule to reach commercialization [18], with the risk of antimicrobial resistance
rapidly developing, crippling its clinical application, or on the opposing end, a new antibiotic might
be so effective it is only used as a last resort therapeutic, thus not widely commercialized. Either
way, the bottom line implies similar risks with considerably lower returns on investment compared
with other drugs [19], which renders antibiotic discovery an unattractive business. In an attempt
to counter this scenario, the European Federation of Pharmaceutical Industries and Associations
consorted with the European Union to establish the largest worldwide life sciences public–private
partnership, the Innovative Medicines Initiative. Through funding and a highly ambitious agenda,
under the New Drugs for Bad Bugs program, this initiative encourages action in areas ranging from
antibiotic discovery, clinical research, through to reshaping the use of antibiotics, in hopes of catalyzing
the approval of novel antibiotics [20].
The systematic procedures—Antibiotic Discovery Platforms (ADPs)—behind the discovery of
major antibiotic classes, which fueled the antibiotic golden age, have become exhausted. Modern
ADPs have yielded redundant discoveries and/or failed in translation to the clinic, which dimmed
the overly optimistic expectations created with the development of novel technologies throughout
the genomics era. From 2004–2009, the overall rate of antibacterial approval was a mindboggling
single drug per year [21], which doubled from 2011–2014 when the FDA approved a still impressively
scarce eight new antibiotics or combinatorial therapies [22]. According to the antibiotic pipeline
surveillance by The Pew Charitable Trusts [23], from 2014 onwards, the situation is slowly improving,
if at all. As seen on Figure 1, the total antibiotic pipeline appears to be timidly increasing, although
the number of drug candidates close to approval (phase III clinical trials and those that have filed
a New Drug Application) or recently approved (phase IV) remains alarmingly low. Despite great
efforts, most approved antibiotics only target either the ribosome, cell wall synthesis machinery and
DNA gyrase or topoisomerase [24,25]. Beyond conventional antibiotics, some interesting therapeutic
alternatives are noteworthy, including bacteriophages, antivirulence strategies, probiotics, vaccines,
immune stimulation, antimicrobial peptides, antibiofilm therapies and antibodies, among others.
Despite some of these alternatives having reached clinical trials, it is estimated that across the next 10
years, over £1.5 billion will be needed to further test and develop them before their clinical impact is
felt [26].
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Figure 1. Evolution of the total antibiotic pipeline and the antibiotic pipeline by stage of development, 
which includes: Clinical Trials ranging from Phase I, to evaluate safety; Phase II, to access 
effectiveness and safety; Phase III, to gather statistically significant data on safety, effectiveness and 
benefits-versus-risk; submission of a New Drug Application, for marketing approval; and lastly, 
Phase IV for post-marketing surveillance. 
2. The Birth of Antimicrobial Chemotherapy 
Traditional behaviors and primitive rituals suggest ancient human use of antibiotics [28,29], 
although the first scientific record of the therapeutic use of antibiotics dates to 1899 when Emmerich 
and Löw explored the therapeutic potential of Pseudomonas aeruginosa extracts. While their 
investigation was discontinued due to inconsistent effects, the antimicrobial effect observed was later 
associated with quorum-sensing molecules [30]. When discussing antimicrobial chemotherapy, 
highlighting the contributions of Pasteur, Lister and Koch to the foundation of medical microbiology 
is a tribute of sorts, for which reviews are available [31–34]. The road towards the first modern 
antimicrobial began in 1854, when Antoine Béchamp produced aniline, via the reduction of 
nitrobenzene with iron in the presence of hydrochloric acid. In 1859, Béchamp produced atoxyl, by 
reacting aniline with arsenic acid, in his pursuit of developing aniline derivatives. Simultaneously, 
Paul Ehrlich noticed that chemical dyes stained specific histological and cellular structures, which 
inspired his side-chain theory in 1897, where he hypothesized about therapy targeting structures 
exclusive to pathogens [35]. Ehrlich, together with Alfred Bertheim and Sahachiro Hata, synthetized 
and screened multiple arsenical derivatives based on Béchamp’s discovery of atoxyl and, by 1907, 
discovered Salvarsan [36], the first antimicrobial that was an effective and safer therapeutic against 
syphilis, which became the most prescribed drug until the introduction of penicillin [37]. 
The systematic application of chemical modifications to expand a library of lead molecules, 
followed by screening its effect on a disease model contributed to the discovery of Neosalvarsan, a 
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During 2011, the director general of the World Health Organization made the clear forewarning that
we are currently “on the brink of losing these miracle cures . . . In the absence of urgent corrective and
protective actions, the world is heading towards a post-antibiotic era, in which many common infections
will no longer have a cure and, once again, kill unabated” [27]. Besides a more efficient management
of antibiotic use, there is a pressing need for new platforms capable of consistently and efficiently
delivering new lead substances, which should attend their precursors impressively low rates of success,
in today’s increasing drug resistance scenario. The present manuscript reviews the discovery timeline
of the major antibiotic classes from an ADPs perspective, highlighting their underlying technological
basis and the context of their application, beginning with the birth of chemotherapy, the establishment
of the Waksman platform, semi-synthesis and fully synthetic antibiotics, followed by the technological
revolution during the genomics era, and the present-day efforts in the post-genomics era.
2. The Birth of Antimicrobial Chemotherapy
Traditional behaviors and primitive rituals suggest ancient human use of antibiotics [28,29],
although the first scientific record of the therapeutic use of antibiotics dates to 1899 when Emmerich
and Löw explored the therapeutic potential of Pseudomonas aeruginosa extracts. While their investigation
was discontinued due to inconsistent effects, the antimicrobial effect observed was later associated
with quorum-sensing molecules [30]. When discussing antimicrobial chemotherapy, highlighting the
contributions of Pasteur, Lister and Koch to the foundation of medical microbiology is a tribute of sorts,
for which reviews are available [31–34]. The road towards the first modern antimicrobial began in 1854,
when Antoine Béchamp produced aniline, via the reduction of nitrobenzene with iron in the presence
of hydrochloric acid. In 1859, Béchamp produced atoxyl, by reacting aniline with arsenic acid, in his
pursuit of developing aniline derivatives. Simultaneously, Paul Ehrlich noticed that chemical dyes
stained specific histological and cellular structures, which inspired his side-chain theory in 1897, where
he hypothesized about therapy targeting structures exclusive to pathogens [35]. Ehrlich, together with
Alfred Bertheim and Sahachiro Hata, synthetized and screened multiple arsenical derivatives based on
Béchamp’s discovery of atoxyl and, by 1907, discovered Salvarsan [36], the first antimicrobial that was
an effective and safer therapeutic against syphilis, which became the most prescribed drug until the
introduction of penicillin [37].
The systematic application of chemical modifications to expand a library of lead molecules,
followed by screening its effect on a disease model contributed to the discovery of Neosalvarsan, a more
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water-soluble derivative with reduced side effects, and laid the foundation of modern pharmaceutical
research. Given its success, the Friedrich Bayer Company explored synthetic chemicals for therapeutic
purposes in the 1920s [38]. The azo compounds, a class of synthetic dyes with antibacterial activity, were
the starting point for the synthesis of diverse structural variants. In 1932, Gerhard Domagk recognized
the curative potential of Prontosil, synthetized by chemists Josef Klarer and Fritz Mietzsch, from studies
on streptococci-infected mice and later, on two dire cases of children in life-threatening situations,
including Domagk’s daughter. Prontosil became commercially available by 1935, simultaneous to
the discovery of its active principle, which was unrelated to the azo functional group or the dye
fraction. In fact, Prontosil is a precursor to the active molecule, sulfanilamide, widely used in the dye
industry, hence not patentable, and whose synthesis was readily achievable. In the following years,
over 5000 derivatives, known as the sulpha drugs, were synthetized, some of which are still used today,
e.g., sulfamethoxazole.
Arguably, it was Alexander’s Fleming ‘accidental’ detection of Staphylococci growth inhibition
around mold colonies in petri dishes, forgotten at his lab throughout a holiday period, that mostly
impacted the future of antimicrobial discovery [39]. Fleming’s observation in 1928 motivated his studies on
the mold’s product, penicillin, regarding its activity spectrum, potency, leukocyte interaction and toxicity.
In fact, it was the first substance noted to present more antibacterial than antileukocytic activity [40].
Fleming’s rigorous methods, and their underlying rational, are still hallmarks for antibiotic discovery.
Nonetheless, Fleming faced problems associated with the large-scale growth of the penicillin-producing
mold and it was not until 1939 that Howard Florey, Norman Heatly and Ernst Chain described a method
that made penicillin sufficiently available for clinical testing. This bioprocess was greatly up-scaled when
Florey and Heatly moved to the USA and Canada, given the necessity of antibiotics imposed by World
War II [41]. Ultimately, their work on bioprocess optimization surpassed penicillin production, as it
promoted the fermentation industry, which is highly relevant for the production of diverse antibiotics
and other medicines such as insulin, erythropoietin, interferon, and antibodies, among others [42].
Although penicillin’s bioprocess scale-up breakthroughs enabled its widespread clinical use
during the late period of World War II, efforts pursued an outperforming chemical synthesis protocol.
During late 1945, penicillin antimicrobial activity was traced to the B-lactam ring [43]. Ernst Chain
believed that fully synthetic penicillin would require new chemical techniques, achieved in 1950 by
John Sheehan, from which the first synthetic natural penicillin V was produced in 1957. The year
after, Sheehan described the production of 6-aminopenicillanic acid (6-APA) via both semi- and fully
synthetic methods, which became a scaffold for multiple C6 sidechain modifications, further discussed
ahead in the context of semi-synthesis.
3. Towards the Golden Era: Waksman Platform
Impelled by the remarkable successes at the beginning of the 20th century, Selman Waksman
adventured into the realm of drug discovery. In 1937, noticing that complex soil bacteria—actinomycetes—
inhibited the growth of other bacteria, Waksman acknowledged that these biological mechanisms, which
evolved from competitive growth [44], could become the conceptual basis of a screening platform for
antibiotic-producing organisms [45]. From 1939 onwards, it is estimated that his systematic agar overlay
process, referred to as the Waksman platform, screened well over 10,000 strains of different microbes [46],
which exemplifies the scalability of this method—a key characteristic for the coming successes. Equally
important, over 90% of clinical antibiotics derive from actinomycetes [10], making these microbes an
antibiotic gold mine of sorts.
The Waksman platform promptly revealed new antimicrobials: actinomycin, streptothricin,
fumigacin and clavacin; but it was not until 1944 that a Streptomyces griseus strain was found to
produce a non-toxic aminoglycoside antibiotic, named streptomycin, which inhibits protein synthesis
by binding to the bacterial 30S ribosomal subunit. At the time, it was not possible to patent natural
products in the USA, but together with Merck lawyers, Waksman convinced the authorities that purified
antibiotics were sufficiently distinct, sparking a new range of business opportunities, a significant
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stride towards economic stimulus that bolstered the antibiotic golden age. Merck obtained FDA
approval for streptomycin [44] and began its commercialization by 1946 for the treatment of tuberculosis
and tuberculous meningitis, and later for pathogens outside penicillin’s spectrum of activity [47].
The Waksman platform revealed various antibiotic classes, many of which are the major antibiotic classes
currently in clinical use, as described next.
Chloramphenicol was originally isolated in 1947 from the actinomycete Streptomyces venezuelae,
thereby introducing the amphenicol class. Chloramphenicol’s antimicrobial activity derives from its
reversible binding to the 50S ribosomal subunit, thereby inhibiting bacterial protein synthesis. It was
the first FDA-approved broad-spectrum antibiotic, displaying excellent tissue and fluid permeability.
However, in the 1960s, various toxicity issues impaired its administration, and it is currently rarely
prescribed [48]. Chlorotetracycline marked the introduction of the tetracycline antibiotic class in 1948,
which also disrupts protein synthesis by acting on the 30S subunit of the ribosome. Chlorotetracycline,
a product of Streptomyces aureofaciens, is characterized by its instability at both ends of the pH scale that
hampers its bioavailability [49].
Macrolides are the second most prescribed class of therapeutic antibiotics, introduced in 1949
with erythromycin and produced by Saccharopolyspora erythrea. Erythromycin binds to a 50S bacterial
ribosomal target, but its therapeutic use was characterized by instability under acidic conditions and
overall poor oral bioavailability [50]. Virginiamycin was the first identified streptogramin, originally
isolated from Streptomyces virginiae in 1952. Streptogramins are a class of antibiotics formed by two
chemically unrelated substances, a polyunsaturated macrolactone and a cyclic hexadepsipeptide.
Either group binds to the 50S subunit of bacterial ribosomes, presenting mediocre activity, but their
synergistic effect empowers its therapeutic application [51].
Unlike the antibiotic classes described thus far, which target bacterial protein synthesis,
glycopeptides disrupt cell wall synthesis. The first antibiotic of the glycopeptide class, vancomycin,
was discovered in 1956 to be produced by Amycolatopsis orientalis and is currently a last resort antibiotic.
Vancomycin interferes with the transpeptidation and transglycosylation steps of the cell wall synthesis,
thereby inhibiting cross-linking and cell wall maturation [52]. Similarly, ansamycins differ from protein
synthesis inhibitors (e.g., amphenicols, tetracyclines, macrolides and streptogramins) and cell wall
synthesis inhibitors (e.g., glycopeptides). For instance, rifamycins inhibit the DNA-dependent RNA
polymerase of prokaryotes. Rifamycin B was first isolated in 1959 from Streptomyces mediterranei (later
classified as Amycolatopsis mediterranei), and despite considerably low antimicrobial effect, it introduced
a unique metabolic target in bacteria [53]. The discovery of fosfomycin came from the isolation of three
Streptomyces strains in 1969. Its antimicrobial effect derives from the inhibition of the initial steps of the
cell wall biosynthesis pathway, disrupting the action of phosphoenolpyruvate synthetase. However,
fosfomycin presents a broad spectrum of activity, making it an appealing antimicrobial [54].
Although the first report of a lipopeptide antibiotic dates to 1947 with the discovery of polymyxin E,
produced by Paenibacillus polymyxa, the therapeutic use of this class was limited to experimentations for
a mere couple of years, given multiple concerning adverse effects, but has recently been reconsidered [55].
The production of daptomycin by Streptomyces roseosporus was revealed in 1980 and although Eli Lilly
and Co. attempted its commercialization, clinical trials were discontinued under the belief that there
was a small window between therapeutic efficacy and safety. As such, this calcium-dependent cyclic
lipopeptide is seen as the precursor of the lipopeptide class of antibiotics, with surpassing antimicrobial
activity in comparison with polymyxin E, albeit limited to Gram-positive pathogens. Interestingly,
daptomycin was revived by Cubist Pharmaceuticals and, with dosing adjustments, reached the
market by 2003 [56]. Moreover, daptomycin’s mode of action is still unclear: permeabilization and
depolarization of the cell membrane being the most probable; interference in cell wall synthesis; and/or
disruption of cellular division are other suggestions. Although more cyclic lipopeptides have been
described, daptomycin remains the only approved therapeutic antibiotic of this class [57].
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4. Onto the Medicinal Chemistry Era: Semi-Synthesis
Antibacterial semi-synthesis is the modification of existing scaffolds, or molecular backbones,
obtained by a fermentative procedure. Historically, most scaffolds originated from the Waksman platform.
Thus, they are the evolutionary outcome of selective pressures, e.g., from the actinomycete-bacteria
‘fight’, and are therefore extremely well fit to reach and bind to their target. However, this does not
translate to therapeutic effectiveness or safety, which can often be improved by means of semi-synthesis,
alongside its chemical stability, reduction of undesirable side effects, among other features that are crucial
in marketing antibiotics, for instance patenting derivatives, which increases profitability of antibiotic
development programs, essential for this generally unattractive business. Semi-synthesis began with
the catalytic hydrogenation of streptomycin, which resulted in dihydrostreptomycin by 1946, and was
characterized by greater chemical stability along with similar antimicrobial activity. Although both
streptomycin and its novel derivative quickly made their way to clinical use, eventually their prescription
has been reevaluated due to ototoxicity concerns [58].
Conversely, it took over a decade before a bioproduction method made penicillin a therapeutic
possibility. While the identification of penicillin’s antimicrobial effect preceded its ‘discovery’, it was
Fleming’s will power that pushed penicillin beyond only being obtainable in small and unstable
quantities. This in turn enabled its semi-synthesis, which expanded penicillin from a single drug to
a range of semi-synthetic derivatives constituting an entire class of antibacterial drugs, the beta-lactams.
These comprise over 60% of antibiotics for human use [59], with a multitude of subclasses and marketed
antibiotics within, as seen in Table 1. The rate at which derivatives with improved properties can be
synthetized kept the upper hand against infectious diseases, a key characteristic of semi-synthesis.
Nonetheless, resistance to these semi-synthetic antimicrobials has been rapidly increasing, which is
thought to be related to their high rate of prescription and highlights the importance of continuously
developing novel semi-synthetic derivatives [60].
Table 1. Beta-lactam subclasses highlighting their diversity with examples of marketed antibiotics.
Subclasses Examples of Marketed Antibiotics
Penicillins
Penicillin G, Penicillin V, Ampicillin, Amoxicillin, Bacampicillin, Cloxacillinm,
Floxacillin, Mezlocillin, Nafcillin, Oxacillin, Methicillin a, Dicloxacillin a,
Carbenicillin b, Idanyl b, Piperacillin b, Ticarcillin b
Cephalosporins
Cefalothin c, Cephradinea c, Cefadroxyl c, Cefazolin c, Cephalexin c, Cefuroxine d,
Cefaclor d, Cefotetam d, Cefmetazole d, Cefonicid d, Cefixime e, Ceftibuten e,
Cefizoxime e, Ceftriaxone e, Cefamandol e, Cefoperazone e, Cefotaxime e, Proxetil
e, Cefprozil e, Ceftazidime e, Cefuroxime Axetil e, Cefpodexime e, Cefepime f,
Ceftobiprole g
Other Minor Subclasses Flomoxef
h, Latamoxef h, Cefoxitin i, Loracarbef j, Imipenem j, Meropenem j,
Panipenem j, Aztreonam k, Carumonam k
a Penicillinase-resistant penicillin; b Anti-pseudomonal penicillin; c First-generation cephalosporin; d
Second-generation cephalosporin; e Third-generation cephalosporin; f Fourth-generation cephalosporin; g
Fifth-generation cephalosporin; h Oxycepham; i Cefam; j Carbapenem; k Monobactam.
Semi-synthetic penicillins are obtained by producing penicillin G, which is hydrolyzed into 6-APA,
purified and later chemically altered, e.g., at the acyl side chain, to achieve various semi-synthetic
penicillins [61]. Another beta-lactam example parallel to penicillins is the semi-synthesis of cephalosporins,
which have reduced the incidence of both side effects and resistance, alongside an additional site for
chemical modification [62]. Cephalosporin C was firstly identified as a metabolite of Cephalosporium
acremonium in 1948. By 1959, 7-aminocephalosporanic acid (7-ACA) was obtained from its hydrolysis under
acidic conditions, thereby introducing the precursor to a multitude of semi-synthetic cephalosporins [63].
Figure 2 exemplifies the evolution of semi-synthetic cephalosporins, their timeline of introduction and the
pros and cons of the succeeding generations marketed so far.
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Figure 2. Evolution of cephalosporin characteristics over semi-synthetic generations. Because each
generation is the result of adding different molecular groups to 7-ACA, characteristics are not necessarily
inherited by succeeding generations. For instance, second-generation cephalosporins had reduced
potency against Gram-positive pathogens, despite their otherwise improved properties.
Another key illustration of semi-synthesis comes from the catalytic hydrogenolysis of chlorotetracycline
(discovered in 1948), which resulted in the semi-synthesis of tetracycline by 1953, although it was later also
found to be a natural product [64]. While semi-synthetic cephalosporins are mostly derivatives of 7-ACA,
obtained via the addition of different molecular groups at the pair of modifiable sites, i.e., C7 and C3’,
semi-synthetic tetracyclines and macrolides are the result of serial structural modifications. Each iteration
requires the chemical manipulation of the previous semi-synthetic derivative, which may preserve its
advantages, but the number of chemical modifications grows proportionally and become increasingly
challenging across a series of semi-synthetic generations. Therefore, less than 10 semi-synthetic tetracyclines
were marketed in the last 60 years, in contrast with over 50 commercialized beta-lactam derivatives.
However, recent advances in fully synthetic routes have reignited the potential of tetracycline derivative
synthesis [49,65], which is crucial given semi-synthesis is one of the major strategies for antibiotic discovery
and particularly important in outpacing the evolution of resistance mechanisms.
5. From the Ground Up: Fully Synthetic Antibiotics
Fully sy thetic antibiotics, beyond introducing novel molecules, enable production at a scale
suitable for clinic l application. For inst nce, chloramphenicol became the first fully synthetic ntibiotic,
whose scaffold originated from a natural product, to reach the clinic in 1949. Unsurprisingly, the rational
of semi-synthesis, that of chemically manipul ting a scaffold, applies to a fully synthetic antibiotic like
chloramphenicol. In fact, replacing the nit o group with me hanesulfonyl resulted in thiamphenicol
1952, which overcame the most conc rning toxicity issues and had greater antimicrobial effect, thereby
improving its clinical application [66]. The discovery in 1953 of the natural product azomycin found
little clinical application but introduced the nitroimidazole class. In 1962, the search for optimized
derivatives revealed metronidazole, currently produced with a fully synthetic protocol, which is
active against the trichomoniasis parasite. Curiously, its activity against anaerobic bacteria was
a fortuitous discovery, for which it is still in use [67]. Analogously to metronidazole, the natural
product fosfomycin only had reasonable clinical application once a racemic synthesis protocol was
developed by Merck, and is still prescribed today [54]. While the advantages of chemically synthetizing
natural products are straightforward, fully synthetic antibiotics also resulted in novel scaffolds. Given
synthetic analogs of pyrimidine and purine bases inhibit bacterial growth, a diaminopyrimidine
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derivative named trimethoprim was introduced in 1962 [68], but only commercialized in 1969 together
with sulfamethoxazole due to in vitro synergies, which are being questioned in light of recent in vivo
observations [69].
Most of the fully synthetic antibiotics discussed have limited application to uncomplicated
infections or as an economic alternative in developing countries. The quinolone class, which was
unexpectedly discovered as a by-product of the synthesis of the antimalarial compound chloroquine,
despite limited activity, was an important scaffold in the synthesis of nalidixic acid in 1962 [70]. Three
more generations, the fluoroquinolones, were later obtained via chemical modification. Quinolones are
currently the third most prescribed antibiotic to outpatients, behind macrolides and beta-lactams [71],
and their antimicrobial effect is traced to the formation of a DNA gyrase-quinolone-DNA complex, which
hampers replication and induces cellular death in both Gram-positive and Gram-negative pathogens.
Another major antibiotic class, macrolides, are produced by semi-synthesis from erythromycin, which
may involve simpler routes (e.g., four steps to derive azithromycin) up to more intricate modifications
(e.g., 16 steps for the drug candidate solithromycin). The recent report of a fully synthetic protocol
that yielded over 300 macrolides [72] brings new hope to this class of antibiotics and portrays the
importance of the fully synthetic platform up to this day, not only in facilitating the synthesis, but also
increasing the diversity of the antibiotics available.
The case of fully synthetic beta-lactams is of paramount relevance since it allowed to more
intricate antibiotics to be synthetized, eventually leading to a panoply of subclasses. Two important
examples are the subclasses of carbapenems and monobactams. Carbapenems have a similar core
structure to penicillins, differing at the C2–C3 double bond and the replacement of C1 sulfur for carbon,
yielding improved potency, spectrum of activity, and better resistance to the action of beta-lactamases.
Currently, 10 carbapenems derivatives have been marketed, or are under clinical development, since
their discovery in 1985. Given that carbapenems have the widest activity spectrum among beta-lactams,
including resistant pathogens, they are currently a first in line option for treating multidrug-resistant
infections [73]. Likewise, monobactams have higher stability regarding beta-lactamases and are
a promising way forward. These monocyclic beta-lactams were introduced to the clinic in 1984 with
aztreonam and are currently being developed towards siderophore moiety, a Trojan horse strategy that
uses the bacterial iron uptake machinery to facilitate entry into Gram-negative bacteria [74].
The class of oxazolidinones is divided into two groups differing in their mode of action. The first
acts on cell wall biosynthesis and was introduced with the natural product cycloserine in 1952, which is
currently produced by synthetic means. Cycloserine is still used as a second-line therapeutic option for
tuberculosis, especially in its multidrug-resistant form. The other group of oxazolidinones was found in
1984 to target protein synthesis and, despite reasonable antimicrobial activity, presented limiting toxicity
issues [75]. From these, the DuPont group synthetized various derivatives from which resulted the
discovery of linezolid, approved in 2000 as the first novel antibiotic class since the discovery of nalidixic
acid, with almost half a century discrepancy [76]. Although no major resistance to linezolid has been
reported, its limited effectiveness against Gram-positive bacteria and toxicity in prolonged treatments
limits its therapeutic use as a last resort alternative against complicated cases of multidrug-resistant
pathogens. Over the last decade, there has been substantial interest in developing novel oxazolidinones,
given its low resistance profile, thus a handful of companies have been developing novel analogues [77].
Semi-synthesis, along with complete chemical routes, have catalyzed the dawn of the medicinal chemistry
era, which together with the Waksman platform, have yielded the vast majority of clinically relevant
antibiotics, characterized by increasing potency and diminishing side effects with succeeding iterations,
which gave mankind the upper hand on infectious diseases.
6. Advent of Genomics: Target-Based Screening
After the successes of the antibiotic golden age, the discovery rate of the underlying ADPs has
decreased, along with an increase in class and multidrug-resistance mechanisms, which has weakened
the therapeutic efficacy of the antibiotic arsenal and revived the issue of infectious diseases. The need
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for a new strategy coincided with the genomics era, which redefined the scientific paradigm governing
antibiotic discovery and shaped new high-tech platforms. During the genomics era (1995–2004), the total
number of sequenced microbial genomes increased from 3 to over 200 [78], and in the post-genomics
era (2004–2014) reached a staggering 30,000 [79]. In this context, the first platform to arise was based
on comparative genomics, where novel targets essential for pathogen survival were identified from
repositories of sequenced and annotated genomes. These targets can encode pathogenicity mechanisms,
highlighted by comparing genome sequences of pathogenic and non-pathogenic strains. Furthermore,
comparing these genomes to those of the host rejects targets that are not exclusive to the pathogen,
which minimizes drug–host interactions, resulting in fewer therapeutic side effects. Figure 3 resumes
the target-based ADP: after target discovery, target validation follows by evaluating if they are essential
for bacterial survival, e.g., with knockout analysis and/or mutational studies. After, the target is cloned,
overexpressed and incorporated in a high-throughput screening (HTS) assay to search for binding agents
from chemical libraries.
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Figure 3. Schematic representation of the target-based antibiotic discovery platform: potential targets
are identified from the genome sequence of pathogens and the host, the products of genes exclusive
and essential for bacteria are incorporated into high-throughput screening assays, which identify drug
candidates suitable for lead optimization and preclinical development. The latter falls outside the
scope of antibiotic discovery, thus it is not discussed.
Given that a manageable number of proteins are exclusive and conserved in bacteria, new MOAs
were expected to surface, so some companies launched pioneering target-based screening programs.
GlaxoSmithKline developed a target list of over 300 bacterial genes from 1995 to 2001, of which
approximately 160 were considered essential for survival, and deemed ‘druggable’ in the search for
broad-spectrum antibiotics [80]. Elitra pharmaceuticals, one of the top 10 start-up companies of 2001,
submitted patents on over 4000 targets after developing a proprietary strategy that identified essential
genes in several pathogens [81]. Although target-based screening is suitable for finding potent inhibitors
of said targets, their inability to reach their target, due to the low permeability of bacterial membranes or
the action of efflux pumps, hinders their activity in vivo. In a physiological context, the bacterial cell
wall is a very efficient barrier against most small molecule drugs. Moreover, said targets may present
functional redundancy. Alongside the aforementioned difficulties, the target-based screening approach
also failed because not all targets could be readily cloned, purified and incorporated into in vitro screening
assays; and in some cases, the oversimplified environment of the assay excludes cofactors and lacks
sensitivity for off-target effects. For instance, Merck found that low guanine–cytosine Gram-positive
pathogens have increased resistance to fatty acid biosynthesis targets when grown on media mimicking
the human host [82], which a target-based assay cannot consider. Also, single gene targets are prone to
single point mutations conferring resistance, thus are more likely to select resistant mutants.
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Despite the massive bacterial genome sequencing coupled with the development of bioinformatics
tools to analyze said sequences, there are still many genes whose biological function has not been
characterized. Moreover, genetic diversity further complicates target-based screening at the level of model
organism selection, e.g., GlaxoSmithKline researchers reported an unrelated copy of genes conferring
resistance in 20% of clinical isolates [83]. Ultimately, antibiotic discovery remains a challenging affair
unattainable with an exclusively target-based genomics approach, and many consider the comparative
genomics platform as rather unsuccessful, since not a single new drug was discovered [84]. Nonetheless,
it sparked a quest towards understanding bacterial physiology, which had unquestionable positive
implications in the development of antimicrobial chemotherapy. The reductionist approach of target-based
screening, e.g., analyzing a single gene/protein (target) outside its biological context, evolved towards
a more holistic phenotypic and pathway-based analysis. Subsequent platforms stemmed from taking
a step back and reviving whole-cell screening, which was the basis of the Waksman platform, and bears the
intrinsic advantage that lead compounds can interact anywhere on the pathway, on multiple constituents
of the network or even on different metabolisms, and most importantly, replicating in vivo conditions.
7. Reverse Genomics: Revival of Cell-Based Screening
The case of anti-tuberculosis drug discovery is a good example of this change in strategy:
researchers moved away from target-based ADPs and returned to cell-based screening [85], with
greater success in the discovery of novel, more diverse, lead molecules for subsequent optimization [86].
In general, cell-based screening results in higher variability and more complex data than the binary
hit/no-hit of target-based screening, which is more difficult to relate with biologic phenomena.
In cell-based assays, after a positive hit, e.g., an interaction of a drug with a microorganism such that
its phenotype becomes altered, counter-screening with human cells allows for cytotoxic evaluation of
drug candidates with antimicrobial activity. Cell-based ADPs first identify antimicrobial activity and
only later endeavor to characterize MOA, and thus are also named reversed genomics, as represented
in Figure 4. This is not necessarily a limitation as the FDA does not require the identification of the
molecular target to initiate clinical trials, or to obtain marketing approval [87].
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Figure 4. Schematic representation of the cell-based antibiotic discovery platform: drug candidates
are identified from cell-based screening assays, a counter-screen excludes cytotoxic compounds, and
subsequently genomics tools are applied to identify MOA. Although MOA is not a requisite, it may
facilitate lead optimization and preclinical development, for instance, structural information on the
target can enable a rational modification of the drug candidate.
In a broad sense, cell-based assays include screening large libraries in a systems-based mentality
in order to evalua e the com lex network of responses that antibiotics elicit [88], and are often termed
phenotypic screening. Typically, if said scre ning probes henotypic changes free of targe hypothesis,
term target-agnostic may be applied. Moreover, cell-based screening may follow a chemocentric
approach, e.g., on c mpounds and i s derivatives presenting a known biolog cal effect. The development
of cell-based screening methods has b en of paramount importance and in its simpl form, these are
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centered on determining the Minimum Inhibitory concentration (MIC) to quantify antimicrobial activity.
MIC assays are still relevant given that they complement other ADPs, for instance, Seiple et al. [72]
developed a fully synthetic protocol for producing macrolide derivatives, where MIC assays were used
to evaluate antimicrobial activity. Efforts to extend cell-based screens beyond conventional MIC assays,
which do not provide insight on the MOA of candidate molecules, have been directed to developing
assays that measure either: mitochondrial activity, by measuring a fluorescent product of a mitochondrial
reaction; cellular integrity, evaluating the release of intracellular enzymes or the uptake of dyes that are
impermeable when the cell is healthy; or measuring ATP content, etc. The reporter gene technology
is still predominant, where the activation and expression of a gene, which yields a quantifiable signal,
e.g., luminescence or fluorescence, ‘reports’ biomolecular interactions. For instance, Hutter et al. [89,90]
developed a HTS assay with a panel of twelve Bacillus subtilis strains, modified with luciferase reporter
genes, to indicate the MOA of various antibiotics with sensitivity ranging from generic pathways,
antibiotic class and the specific MOA of some drugs.
Alternatives to MIC-type assays require genetic manipulation and/or the use of a label, either
in the form of a fluorescent or radioactive molecule, or a reporter gene. This is a limiting factor
since, on the one hand, genetic manipulation implies a priori knowledge and on the other hand, the
indication of gene transcription using a reporter gene may not always be coherent with alterations of
enzymatic activity, thereby crippling the inherent sensitivity of these assays. Moreover, these signal
transduction events can take considerable time to become detectable, thus limiting assay capacity
and throughput [91]. In addition to the impact of a reporter gene, some of these labeled assays
are limited on miniaturization. Despite said issues, cell-based screening still contributes greatly
towards advancing antibiotic discovery, for instance, in neglected diseases such as malaria and human
African trypanosomiasis [92]. For the latter, phenotypic screening lead to the discovery of fexinidazole
(a nitroimidazole) which has been recently approved as the first oral therapy for human African
trypanosomiasis and Chagas disease [93].
Eder et al. reviewed the discovery platforms of first-in-class small molecule drugs, in particular
the role of target- versus cell-based screening [94]. First-in-class drugs act on a new target or biological
pathway. Between 1999 to 2008, phenotypic screening was more productive. However, in the period
up to 2013, target-based approaches delivered most first-in-class drugs. Given the period ranging from
the burdensome process of drug discovery until commercialization, there is a latency between the
timeline of said review and the timeline presented in this manuscript. Concerning antibiotics, from
2000 to 2015, only five first-in-class new drugs were marketed: linezolid, daptomycin, retapamulin,
fidaxomicin and bedaquiline [95]. Retapamulin binds to the 50S ribosomal subunit, fidaxomicin acts at
the “switch” region of the bacteria RNA polymerase and bedaquiline specifically inhibits the ATPase
of Mycobacterium tuberculosis. From these five new drugs, three are derived from natural products
(daptomycin, retapamulin and fidaxomicin), and only two were chemically synthesized (linezolid and
bedaquiline) [90].
Historically, the success of antibiotic therapy relied on the discovery of natural scaffolds that
were chemically optimized or produced. As such, it remains a rational decision to continuously
develop screening strategies that probe natures repositories [96], especially using cell-based assays [97].
In fact, the major antibiotic scaffolds currently in use are derived from natural products, except for
fluoroquinolones, sulphonamides and trimethoprim [98]. New cell-based ADPs should identify
molecules with antimicrobial activity without the limitations of a label. Moreover, these assays would
ideally provide insight on MOA whilst being capable of screening very large libraries, as isolated
projects have very low rates of success [99].
8. Post-Genomics: Transcriptomics, Proteomics and Lipidomics
Biological research tends towards specialization, through increasingly focused and localized
research; however, system-wide understanding of the biological constituents and their interactions
is gaining importance. It is now possible to extract, handle and interpret information from much
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higher dimension and diverse origins, such as transcripts (i.e., transcriptomics), proteins (proteomics),
and other molecules such as lipids (lipidomics), etc. The influence of these omics technologies on the
field of antibiotic discovery is undisputable, especially in understanding antibiotics MOA, identifying
novel targets, and supplying insights to bacterial metabolism and physiology. Given the importance of
screening in the ADPs discussed thus far, this mindset should be the backbone of future platforms.
However, neither transcriptomics, proteomics nor lipidomics have matured to the throughput capacity
of cell-based screening assays, and therefore are not the core technology of any ADP. These technologies
convey insight on the biomolecules they probe, and not the holistic dynamics of bacterial metabolism,
thereby serving as complementary, albeit crucial, tools for the antibiotic discovery process. Since
a post-genomics ADP is yet to be developed, this section focusses on the technological basis and
contribution of these post-genomics techniques to the field of antibiotic discovery.
Initial transcriptomics technologies were hybridization-based, e.g., Northern Blotting and
microarrays [100]. Microarrays became the reference by mid-1990s [101] until next-generation
sequencing extended to transcriptomics, which copes better with high genetic variation and non-specific
hybridizations, as well as being label-free, e.g., unbiased and with a greater upper limit of detection.
RNA-seq outperforms microarrays (90% versus 76%) in predicting differentially expressed genes.
However, both technologies similarly estimated the MOA of anti-cancer drugs [102]. However, RNA-seq
enables studying non-coding RNA, which has a regulatory role in microbial responses to antibiotics, and
therefore can be an alternative for new antimicrobial targets and/or novel combinatorial therapies [103].
Although next-generation sequencing [104], unbiased transcriptomics [105] and non-coding RNA [106]
technologies have been applied to drug discovery in general, few studies discuss their application to
antibiotic discovery. Whole-genome expression profiling elucidates the molecular and cellular responses
to antibiotic stresses, which is particularly helpful for MOA determination, still a major gap in the field of
antibiotic discovery. For instance, Salvarsan’s MOA remained unclear over a century since its discovery,
and its chemical structure has only recently been fully elucidated [107]. In general, antimicrobials of the
same class, thus with similar MOA, give rise to analogous transcriptional responses, which provides
insight on the MOA of uncharacterized antibiotics [108]. For instance, the cell-based HTS assay developed
by Hutter et al. [89,90] used transcriptomics to characterize the effect of various antibiotics, which then
guided the genetic manipulation of a bacterial panel that ‘reports’ lead molecules MOA. Additionally,
these signature responses are also being used to elucidate resistance mechanisms [109].
Genome expression technologies expand beyond the transcript level to biological events at the
level of proteins. Not only do these occur without transcriptome alterations, but the instability of
bacterial RNA raises both conceptual and technological limitations, which stress the need to complement
transcriptomics with proteomics. Early proteomics studies relied on 2D gel-based assays or on Difference
Gel Electrophoresis [110], which require high-purity protein samples given their little sensitivity for
low-abundance proteins, co-migration of proteins, and different modifications on the same protein [111].
Moreover, gel-based techniques are laborious, poorly automatable, and therefore difficult to apply
in large-scale studies, so the evolution of MS coupled with chromatographic separation presents an
alternative [112]. Proteomics has contributed towards identifying novel antimicrobial targets [113],
understanding resistance mechanisms to therapeutic antibiotics [114], and to elucidate MOA [115],
although unable to fully characterize MOA [116]. Importantly, the application of transcriptomics and
proteomics technologies sheds new light on the function of various genes, leading to updates on existing
annotations, and to improved understanding of bacterial metabolism and physiology. Although not at
the core of any ADP, these technologies complement other ADPs, revealing information that is building
the way forward. Since proteins interact with different biomolecules, including nucleic acids and lipids,
specialized techniques have been developed to probe said interactions [117]. Moreover, within the realm
of proteomics, the field of phosphoproteomics has ‘spun-off’. Although this type of post-translational
modifications was thought to be exclusive to eukaryotes, it affects bacterial homeostasis, virulence [118],
and signal transduction [119]. Virulence mechanisms are interesting since the machinery used by bacteria
to cause disease, for instance tyrosine kinases and phosphatases, are structurally different from the hosts
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and therefore can be exclusively targeted. Further descriptions on phosphoproteomics for drug discovery
exist, albeit outside the scope of infectious diseases [120].
Understanding the physiological role of lipids, especially at the molecular level, has been
considerably limited due to a technological gap that is being filling with very selective and sensitive
lipidome characterization studies using MS, and combining various targeted and non-targeted
approaches [121]. To achieve the required lipid separation, various chromatographic methods are
routinely applied in combination with MS, for instance hydrophilic interaction liquid chromatography
or gas chromatography [122]. Besides their structural function, lipids take part in a panoply of different
biological events including signaling, trafficking and even metabolite functions. Regarding infectious
diseases, an example of the application of lipidomics is the characterization of pathogenic microbe’s
cell wall, thereby unveiling its regulation and role in pathogenesis. This has revealed essential enzymes
involved in fatty acid synthesis that are conserved across many of the most clinically relevant pathogens,
e.g., FabI, FabH, FabF and acetyl-CoA carboxylase. As such, inhibitors of said enzymes are promising
targets for future development [123], especially for persistent mycobacteria infections that use fatty
acids as a carbon source [124].
9. Post-Genomics: From Metabolomics towards Meta-omics
Gene expression data from transcriptomics and proteomics faces challenges, for instance, increases
in RNA levels might not coherently result in changes at the protein level, added to conceptual and
technological limitations associated with bacterial RNA instability, and differences in protein levels are
often poor estimators of metabolic activity. Consequently, interest in small-molecule metabolites has
also emerged [125]. Metabolomics provides a more in-depth view of the biological reality governing
microbial metabolism, using complex analytical methods like NMR and chromatographic techniques
associated with MS, alongside advanced data analysis algorithms [126,127]. Since bacterial responses
to antibiotics begins rapidly and encompasses a variety of pathways, metabolomics is well suited to
elucidating the MOA. For instance, Hoerr et al. [128] explored NMR-based metabolomics to differentiate
the MOA of nine antibiotics on Escherichia coli. Moreover, metabolomics complements other omics,
for instance, rhodomyrtone’s antimicrobial activity was identified via phenotypic screening, but its
MOA was revealed with proteomics and metabolomics. Specifically, rhodomyrtone cripples capsule
biosynthesis enzymes and metabolites of Streptococcus pneumoniae [129]. Additionally, it is possible
to construct metabolic networks that aggregate catalytic activity (i.e., enzymes) alongside its coding
and expression (i.e., genes, and their transcriptional and translational control). Over 50 networks
of different organisms have been described, which sparked a new approach for antimicrobial target
discovery [130].
Metagenomics, and meta-omics in general, have reinforced natural product discovery, which
has had a central role in antibiotic discovery, and chemotherapy in general, ranging from oncological
to immunologic treatments, e.g., approximately 50% of all FDA-approved therapeutics are natural
products or their derivatives [131]. Metagenomic studies estimated that only 10% of natural products
have been identified, so the suggestion that only 1% of the complete natural products repository
has been investigated comes as no surprise [132]. Therefore, the search for new drugs from natural
sources is being pursued with renewed hopes [133]. In this regard, sampling new natural product
sources, such as plants and marine organisms [134], and endophytes or epiphytes [135], is expected to
reveal an even wider range of metabolic pathways with potential therapeutic applications. Moreover,
exploring microorganisms unculturable in traditional laboratory conditions, or certain pathways not
activated in typical laboratory conditions, requires efforts to develop adequate protocols. Given the
meta-omics revelation of natures ‘untapped’ repositories, these could very well be the next ‘gold mine’
after the actinomycete-fueled Waksman platform, thereby justifying such efforts.
An interesting device, the iChip, allows for the high-throughput cultivation of microbial species in
their natural habitat, with a growth recovery of 50% versus 1% of traditional recovery methods, thereby
giving access to otherwise ‘uncultivable’ microorganisms [136]. The iChip was used to collect extracts
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from 10,000 isolates from which a new species of Beta-proteobacteria, thought to belong to a new
genus related to Aquabacteria, was shown to produce an antibiotic named teixobactin, a peptidoglycan
synthesis inhibitor. Teixobactin is mostly active against Gram-positive pathogens, some of which are
drug-resistant, and its bactericidal activity even surpasses that of vancomycin (a last resort antibiotic),
along with no indication of resistance mechanisms currently existing [137]. Metagenomics enables
a different approach, instead of attempting to grow these ‘uncultivable’ microorganisms, sequences
of interest can be identified from the metagenomes, which can then be cloned and expressed in
laboratory-friendly microbes. This avoids in situ cultivations, like with the iChip, or the burdensome
tasks of deciphering the conditions required for growth or activation of unexplored pathways, and
could provide novel molecules for antibiotic discovery [138].
The interaction of antibiotics with the human microbiome has also been enabled by meta-omics, which
has created further opportunities for antibiotic discovery [139]. In fact, human-associated metagenomic
studies revealed gene clusters with antibiotic potential. For instance, in the case of Staphylococcus lugdunensis
nasal colonization, these commensal bacteria inhibit the presence of Staphylococcus aureus strains, thereby
preventing opportunistic infections. This effect was traced to the production of lugdunin, a novel class
antibiotic (macrocyclic thiazolidine peptides) produced by S. lugdunensis, which has bactericidal activity
on key pathogens and importantly, presents a reduced risk of resistance development [140]. Likewise,
lactocillin, a novel thiopeptide antibiotic, was identified from the vaginal microbiota and demonstrated
considerable activity against typical pathogens [141]. On a different note, recurrent Clostridium difficile
infections have been treated with complete microbiome transplantation [142], which is a ‘brute-force’
alternative in comparison to pinpointing the key molecular agent responsible for the regulation between
commensal flora and pathogenic agents. These studies suggest that either introducing healthy microbiota,
the targeted manipulation of commensal microbial populations, or even the purified molecular agents of
commensal bacteria can be novel therapeutics, which has been enabled by meta-omics technologies.
As seen, the technologies introduced in the post-genomics era have contributed towards new
opportunities in antibiotic research, although these have not been at the core of any ADP. The case
of teixobactin, for instance, heavily relied on the revelations brought by meta-genomics and the
technologies required to build a device such as the iChip. However, identifying which of the molecules
recovered with the iChip have antimicrobial activity, along with insights into their MOA, were
revealed with cell-based assays in a reverse genomics platform. Since phenotypic screening has had
greater success in revealing first-in-class molecules, it is a great starting point for ADPs. However,
the drawback is the reduced mechanistic information derived, for which the omics technologies
supply accelerated insight on the MOA, including the molecular target and its regulation. Then, with
the required mechanistic information, target-based screening can be applied in order to optimize
lead molecules into best-in-class medicines [143]. Although most new antibiotics in late clinical
development belong to existing classes [144], the paradigm of combining target- and cell-based
screening brings renewed hope moving forward. Additional opportunities may arise from revisiting
compounds that were discontinued at early stages of their development. In that sense, Farrell et al. [145]
launched AntibioticDB, a database of antibiotics at all stages of development, including those that were
discontinued. While some compounds were legitimately abandoned, e.g., in light of clinical results,
due to toxicity issues or inferior effectiveness, the majority were discontinued for unknown reasons,
and some were discarded for circumstantial reasons. If re-evaluated with novel chemical synthesis
methods, or with post-genomics technologies, many abandoned compounds may prove to be effective
therapeutics. The case of daptomycin is a good example of how a compound can be revived, nearly 20
years after its abandonment, and still become the most financially successful intravenous antibiotic in
the US [56].
10. Conclusions
Once considered a resolved health issue, infectious diseases have resurfaced as a topic requiring urgent
action. Antibiotic discovery has come a long way since the success of the Waksman platform, semi-synthesis
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and fully synthetic ADPs. As seen, the establishment of systematic procedures—platforms—was crucial for
the discovery of the major antibiotic classes in use. Given the limitations of target-based screening, cell-based
ADPs were revived during the genomics era. While some consider the genomics era platforms disappointing,
the importance of the lessons learned should not be minimized. Considerable technological advances have
given researchers unprecedented access to biological events and repositioned the mind-set for antibiotic
research in a systems biology context. Paradoxically, in the field of antibiotic discovery, the more we know
the less we can discover. Although not at the core of any ADPs, omics technologies have been proven of
unquestionable value as auxiliary tools for antibiotic discovery. Importantly, cell-based screening requires
MOA characterization, for which omics technologies are indispensable. Despite offering added-value
information on biological events, their reduced throughput capacity alongside complementarity, in terms
of resourcing to multiple omics simultaneously, implies a limited application in ADPs aiming to screen
large libraries, for instance the reservoir of untapped natural products, which is likely the next antibiotic
‘gold mine’. There is a void between phenotanypic screening (high-throughput) and omics-centered assays
(high-information), where some mechanistic and molecular information complements antimicrobial activity,
without the laborious and extensive application of various omics assays. Given the novelty of the various
omics technologies, we are yet to extract their full potential and it seems feasible that these technologies
will mature to fulfill this gap. Alternatively, innovative technologies favoring high-throughput may be
developed, even by sacrificing molecular sensitivity to some extent. In any case, the increasing need for
antibiotics drives the relentless and continuous research on the foreground of antibiotic discovery. This is
likely to expand our knowledge on the biological events underlying infectious diseases and, hopefully,
result in better therapeutics that can swing the war on infectious diseases back in our favor.
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